Lipoprotein receptor-related protein 4 autoantibodies in myasthenia gravis: Where are we and where are we going?

Shunya Nakane*, Osamu Higuchi, Koutaro Takamatsu, Akihiro Mukaino, Yasuhiro Maeda, Hidenori Matsuo, Yukio Ando

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction that leads to fatigue of skeletal muscles and fluctuating weakness. The pathogenesis of MG is sufficiently diverse to include autoimmune mechanisms. In most patients with MG, autoantibodies against acetylcholine receptor can be detected. In a smaller proportion of patients without anti-acetylcholine receptor antibodies, autoantibodies to muscle-specific kinase and low-density lipoprotein receptor-related protein 4 (LRP4) are present. LRP4 is critical for neuromuscular junction formation and maintenance. A multimolecular complex is formed among agrin, LRP4 and muscle-specific kinase that is critical for agrin signaling. The presence of anti-LRP4 antibodies is associated with mild symptoms of MG, while thymomas are rarely observed in association with MG and LRP4 antibodies. We review recent findings on the pathogenesis, clinical features and treatment of LRP4 MG.

Original languageEnglish
Pages (from-to)79-84
Number of pages6
JournalClinical and Experimental Neuroimmunology
Volume10
Issue number2
DOIs
StatePublished - 2019/05

Keywords

  • acetylcholine receptor
  • autoantibody
  • low-density lipoprotein receptor-related protein
  • myasthenia gravis
  • neuromuscular junction

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Lipoprotein receptor-related protein 4 autoantibodies in myasthenia gravis: Where are we and where are we going?'. Together they form a unique fingerprint.

Cite this